GLP-1 medicines have transformed the treatment of type 2 diabetes and obesity. These medicines can help lower blood sugar, reduce appetite, promote weight loss and, for selected medicines and patients, provide important cardiovascular and kidney-related benefits.
If you are searching for a GLP-1 specialist in Ahmedabad, Dr. Moxit Shah, DM Endocrinology, provides personalized treatment for diabetes, obesity, thyroid disorders and other endocrine conditions.
What Are GLP-1 Medicines?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the intestine after eating.
GLP-1 receptor agonists mimic some of the actions of this hormone. They can:
- Increase glucose-dependent insulin secretion
- Reduce inappropriate glucagon secretion
- Slow stomach emptying
- Reduce appetite and food intake
- Improve blood glucose levels
- Promote weight loss
Because of these effects, GLP-1-based medicines are used in the management of type 2 diabetes and obesity.
Current diabetes guidelines recommend considering GLP-1-based therapies particularly when weight management or cardiovascular, kidney or other metabolic considerations are important.
Which Medicines Are GLP-1 Medicines?
Some commonly used GLP-1 receptor agonists include:
Semaglutide
Semaglutide is available in different formulations and doses for different indications.
It can be used in appropriate patients with type 2 diabetes and is also used at obesity-treatment doses for chronic weight management.
Semaglutide has become one of the most widely recognized GLP-1 medicines because of its effects on both blood glucose and body weight.
Liraglutide
Liraglutide is another GLP-1 receptor agonist used for diabetes treatment and, at a different dose, for chronic weight management in appropriate patients.
Dulaglutide
Dulaglutide is a once-weekly GLP-1 receptor agonist used for the treatment of type 2 diabetes.
Tirzepatide – A Dual GIP/GLP-1 Medicine
Tirzepatide is not a pure GLP-1 receptor agonist. It activates both the GIP and GLP-1 receptors.
It can produce substantial improvements in blood glucose and body weight and has become an important option for selected people with type 2 diabetes and/or obesity.
The 2026 ADA Standards identify semaglutide and tirzepatide as particularly effective options for people with diabetes and overweight or obesity when clinically appropriate.
What Are the Main Indications for GLP-1 Medicines?
1. Type 2 Diabetes
GLP-1-based medicines are an important treatment option for people with type 2 diabetes.
They can be particularly useful when:
- HbA1c is above the individualized target
- The patient is overweight or has obesity
- Weight loss is an important treatment goal
- Hypoglycemia should be minimized
- Cardiovascular risk is an important consideration
- Kidney disease is present
- Conventional treatment is insufficient or unsuitable
The choice depends on the individual patient’s medical history and treatment goals.
2. Diabetes With Overweight or Obesity
For people with type 2 diabetes and overweight or obesity, modern diabetes treatment increasingly considers both glucose control and weight management.
The ADA Standards of Care 2026 recommend prioritizing glucose-lowering medicines with beneficial effects on weight in people with diabetes and overweight or obesity. GLP-1 receptor agonists and dual GIP/GLP-1 therapy such as semaglutide and tirzepatide are among the preferred options when appropriate.
3. Obesity and Weight Management
GLP-1-based medicines can also be used specifically as anti-obesity medications in appropriately selected individuals.
They are generally considered along with:
- Nutrition intervention
- Physical activity
- Behavioral modification
- Adequate sleep
- Long-term lifestyle management
Obesity pharmacotherapy is generally considered for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with an obesity-related medical condition, according to commonly used regulatory criteria such as those described by the ADA for FDA-approved obesity pharmacotherapy.
Importantly, BMI is only one component of the clinical assessment. The decision to start medication should consider the patient’s overall health, complications, previous weight-loss attempts and treatment goals.
4. Diabetes With Cardiovascular Risk
Some GLP-1 receptor agonists have demonstrated cardiovascular benefits in people with type 2 diabetes and appropriate cardiovascular risk profiles.
Therefore, the choice of diabetes medicine is no longer based only on HbA1c.
A modern diabetes treatment plan may consider:
Blood sugar + body weight + heart health + kidney health + liver health + hypoglycemia risk.
This is one reason GLP-1-based therapy has become an important part of modern diabetes care.
5. Type 2 Diabetes With Kidney Disease
GLP-1 receptor agonists may be particularly useful in selected patients with type 2 diabetes and chronic kidney disease.
The 2026 ADA Standards recommend an SGLT2 inhibitor or a GLP-1 receptor agonist with demonstrated benefit in appropriate people with type 2 diabetes and CKD. In advanced CKD, GLP-1 receptor agonist therapy may be preferred for glycemic management in appropriate patients.
Treatment should always be individualized according to kidney function and the overall clinical situation.
6. Diabetes, Obesity and Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) frequently occurs alongside type 2 diabetes and obesity.
Weight reduction and improved metabolic health are important components of management.
The 2026 ADA Standards recognize a role for GLP-1 receptor agonists with demonstrated benefits in MASH, and dual GIP/GLP-1 therapy may also be considered in selected patients.
How Do GLP-1 Medicines Help With Weight Loss?
GLP-1-based medicines can affect several mechanisms involved in appetite regulation.
They can:
- Reduce hunger
- Increase satiety
- Reduce food intake
- Slow gastric emptying
- Improve blood glucose control
Patients often report feeling full after eating smaller portions.
However, GLP-1 medicines are not magic weight-loss injections. Long-term weight management still requires appropriate nutrition, physical activity and behavioral changes.
Who May Be a Candidate for GLP-1 Treatment?
A doctor may consider GLP-1-based treatment in an adult with:
Type 2 diabetes
particularly when glucose control needs improvement and weight or cardiovascular considerations are important.
Obesity
particularly when lifestyle intervention alone has not produced sufficient or sustained weight loss.
Overweight with obesity-related complications
such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea or other metabolic complications.
Type 2 diabetes with cardiovascular or kidney disease
when a GLP-1 medicine with demonstrated benefit is appropriate.
The exact indication, dose and choice of medication depend on the specific drug and its regulatory approval.
Who Should Not Take GLP-1 Medicines?
GLP-1 medicines are not suitable for everyone.
Before prescribing them, a doctor should review:
- Medical history
- Previous pancreatitis
- Gallbladder disease
- Gastrointestinal problems
- Kidney function
- Other medications
- Pregnancy plans
- Personal and family history relevant to the specific medicine
Certain GLP-1 products have specific contraindications and precautions. Therefore, these medicines should not be started simply because someone wants to lose weight.
Common Side Effects of GLP-1 Medicines
The most common adverse effects are gastrointestinal.
These may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Reduced appetite
Symptoms are often more prominent when treatment is started or the dose is increased.
Gradual dose escalation is commonly used to improve tolerability.
Are GLP-1 Medicines Safe?
GLP-1 medicines can be safe and effective when appropriately prescribed and monitored.
However, they are prescription medicines and should not be taken without medical supervision.
Patients should seek medical advice if they develop significant or persistent:
- Vomiting
- Severe abdominal pain
- Dehydration
- Severe gastrointestinal symptoms
- Symptoms suggestive of gallbladder disease
- Symptoms of hypoglycemia, particularly when combined with insulin or insulin-secretagogue medicines
GLP-1 Medicines Are Not the Same as “Weight-Loss Injections”
An important distinction is that different products, doses and formulations can have different approved indications.
A medicine approved for type 2 diabetes should not automatically be assumed to be interchangeable with a formulation or dose approved for obesity.
For example, semaglutide products may have different approved uses and dosing schedules.
Therefore, patients should use the exact product and dose prescribed by their doctor.
Should Everyone With Obesity Take a GLP-1 Medicine?
No.
GLP-1 treatment should be individualized.
A doctor may first evaluate:
- BMI and waist circumference
- Blood glucose and HbA1c
- Blood pressure
- Lipid profile
- Kidney function
- Liver health
- Eating pattern
- Physical activity
- Previous weight-loss attempts
- Current medications
- Obesity-related complications
The aim is to select the treatment that provides the best balance between benefit, safety, affordability, tolerability and long-term adherence.
Can GLP-1 Medicines Be Used With Other Diabetes Medicines?
Yes.
GLP-1-based therapy may be combined with other diabetes medicines when clinically appropriate.
However, when combined with insulin or medicines that increase insulin secretion, the risk of hypoglycemia may increase, and treatment may need to be adjusted by the treating physician.
Patients should never independently change insulin or other diabetes medication doses.
What Happens After Stopping a GLP-1 Medicine?
GLP-1-based obesity treatment is generally considered a long-term treatment strategy when clinically indicated.
Stopping effective obesity medication can result in weight regain in some patients.
The 2026 ADA Standards emphasize that obesity pharmacotherapy intended for chronic treatment may need to be continued beyond the initial weight-loss goal to maintain health benefits.
The decision to continue, reduce or stop treatment should therefore be individualized.
GLP-1 Medicines vs Lifestyle Changes
GLP-1 medicines do not replace healthy lifestyle habits.
The best outcomes usually come from combining appropriate pharmacotherapy with:
- Protein- and fiber-rich nutrition
- Appropriate calorie intake
- Regular physical activity
- Resistance training
- Adequate sleep
- Behavioral strategies
- Regular medical follow-up
Medication and lifestyle treatment should work together rather than being viewed as alternatives.
Frequently Asked Questions About GLP-1 Medicines
What is the best GLP-1 medicine for weight loss?
There is no single best medicine for everyone. Semaglutide and tirzepatide are among the most effective currently available options for many appropriately selected patients, but the choice depends on the patient’s medical condition, indication, contraindications, tolerability, cost and treatment goals.
Can GLP-1 medicines cure diabetes?
No. They can significantly improve glucose control, and some people may achieve diabetes remission with substantial weight loss and lifestyle intervention, but GLP-1 medicines should not be described as a permanent cure for diabetes.
Can non-diabetic people take GLP-1 medicines?
Yes, certain GLP-1-based medicines have approved indications for chronic weight management in appropriately selected people who do not have diabetes. The specific indication depends on the medicine and local regulatory approval.
Are GLP-1 medicines addictive?
GLP-1 receptor agonists are not considered addictive drugs. However, obesity is a chronic disease, and stopping effective treatment can lead to recurrence of appetite, weight gain and metabolic risk in some patients.
Do GLP-1 medicines cause muscle loss?
Weight loss can include loss of lean mass as well as fat mass. Adequate protein intake and resistance exercise are important during weight-loss treatment, and nutritional status should be monitored, particularly with substantial weight loss.
Can I buy GLP-1 injections without consulting a doctor?
GLP-1 medicines should be used under appropriate medical supervision. Patients should also be cautious about unapproved or improperly compounded products. Regulatory authorities have raised safety concerns regarding non-approved compounded GLP-1 products.
GLP-1 Treatment in Ahmedabad
GLP-1 medicines have changed the way doctors approach diabetes, obesity and metabolic health.
However, choosing a GLP-1 medicine is not simply about selecting an injection for weight loss. The correct treatment depends on the patient’s diabetes status, BMI, cardiovascular risk, kidney function, liver health, medications, lifestyle and individual goals.
Dr. Moxit Shah, DM Endocrinology, provides specialist evaluation and individualized treatment for:
- Diabetes
- Obesity and weight management
- GLP-1 therapy
- Thyroid disorders
- Metabolic disorders
- Other endocrine conditions
Looking for a GLP-1 Specialist in Ahmedabad?
If you are considering semaglutide, tirzepatide or other GLP-1-based medicines for diabetes or weight loss, consult an endocrinologist before starting treatment.
Dr. Moxit Shah, DM Endocrinology
Vishuddha Endocrine Clinic
Elite Magnum, Bhuyangdev Cross Road, Memnagar/Ghatlodia, Ahmedabad
Medical Disclaimer
This article is intended for general educational purposes and does not replace a consultation with a qualified medical professional. GLP-1 medicines are prescription treatments and should be used only after appropriate medical evaluation. Indications and approved products may vary by country and may change over time.
